A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Trial Profile

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2013

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Dainippon Sumitomo Pharma
  • Most Recent Events

    • 17 Nov 2013 New trial record
    • 09 Oct 2013 Efficacy and tolerability results from a pooled analysis presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top